|
|
||||||||
Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada
Correspondence: Peter Dickie, 1-40 HMRC, University of Alberta, Edmonton, AB T6G 2S2, Canada. E-mail: peter.dickie{at}ualberta.ca
HIV transgenic mice bearing multiple copies of a noninfectious
(
gag/pol) proviral DNA were tested for the systemic
production of nitric oxide (NO). Serum levels of NO metabolites were
reduced about 50% in HIV transgenic mice compared with nontransgenic
sibling mice. This difference persisted when NO production was induced
with peritoneal injections of bacterial endotoxin (LPS). Peritoneal
inflammatory macrophages, but not resident peritoneal macrophages,
derived from HIV-1 transgenic mice and activated in vitro with LPS and
IFN-
(or tumor necrosis factor
and IFN-
) also produced about
50% less NO than did macrophages harvested from nontransgenic
littermates. Isogenic, transgenic mice bearing mutated nef
or vpr genes had normal serum levels of NO metabolites and
their macrophages produced normal levels of NO when stimulated. An
explanation for the reduced NO response of HIV[Vpr+Nef+] macrophages
was not apparent from measured levels of iNOS expression, viral gene
expression, or arginase activity in activated macrophages. Inhibition
of nitric oxide synthase (NOS) isoforms with L-NAME or
aminoguanidine blocked time-dependent increases in HIV gene expression
in activated macrophages cultured ex vivo. Inhibition with
L-NAME occurred despite high levels of NO generated by
iNOS, and exogenously supplied NO induced HIV gene expression only
weakly, suggesting that cNOS had the greater influence on proviral gene
induction. This system is presented as a model of HIV-1 proviral gene
expression and dysfunction in macrophages.
Key Words: transcription arginase TNF-
NOS Nef Vpr
This article has been cited by other articles:
![]() |
E. R. Kline, D. J. Kleinhenz, B. Liang, S. Dikalov, D. M. Guidot, C. M. Hart, D. P. Jones, and R. L. Sutliff Vascular oxidative stress and nitric oxide depletion in HIV-1 transgenic rats are reversed by glutathione restoration Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2792 - H2804. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |